Pages that link to "Q37217409"

The following pages link to Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. (Q37217409):

Displaying 12 items.

• Physical interventions to interrupt or reduce the spread of respiratory viruses (Q24235375) (← links)
• Physical interventions to interrupt or reduce the spread of respiratory viruses (Q24240668) (← links)
• Social, economic, and health impact of the respiratory syncytial virus: a systematic search (Q26852865) (← links)
• The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection (Q26864494) (← links)
• Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity (Q27010165) (← links)
• Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI). (Q36054311) (← links)
• Management of acute viral bronchiolitis in children: Evidence beyond guidelines (Q37105886) (← links)
• Viral respiratory burden in moderate-to-late preterm infants. (Q38117794) (← links)
• Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs (Q38365417) (← links)
• Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands (Q40836385) (← links)
• Respiratory viruses in neonates hospitalized with acute lower respiratory tract infections. (Q54292169) (← links)
• Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high‐risk infants in Japan (Q85054433) (← links)